PI3K/VEGFR2-IN-1 是一种有效的双重PI3K/VEGFR2抑制剂，抑制 PI3K 和 VEGFR2 的IC50值分别为 2.21 和 68 μM。PI3K/VEGFR2-IN-1 诱导细胞凋亡 (apoptosis)。PI3K/VEGFR2-IN-1 可用于癌症的研究。
| 生物活性 | PI3K/VEGFR2-IN-1 is a potent dualPI3K/VEGFR2inhibitor withIC50values of 2.21 and 68 μM forPI3Kand VEGFR2, respectively. PI3K/VEGFR2-IN-1 inducesapoptosis. PI3K/VEGFR2-IN-1 can be used in research ofcancer[1]. |
| IC50& Target[1] | PI3K 2.21 μM (IC50) | VEGFR2 68 μM (IC50) |
|
体外研究
(In Vitro) | PI3K/VEGFR2-IN-1 (compound 8; 1.56-100 μM; 24 h; HePG2, MCF-7, Hela, and PC3 cells) inhibits cell proliferative in a dose-dependent manner[1].
PI3K/VEGFR2-IN-1 (10 mg/mL; 24 h; MCF-7 and Hela cells) arrests cell cycle at G1/S phase and induces apoptosis[1].
Cell Viability Assay[1] | Cell Line: | HePG2, MCF-7, Hela, and PC3 cells | | Concentration: | 1.56-100 μM | | Incubation Time: | 24 hours | | Result: | Had antitumor activity with IC50values of 7.94, 9.73 , 11.58, and 17.49 μM for Hela, HePG2, MCF-7 and PC3 cells, respectively. |
Cell Cycle Analysis[1] | Cell Line: | MCF-7 cells | | Concentration: | 10 mg/mL | | Incubation Time: | 24 hours | | Result: | Arrested cell cycle in G1/S phase at 24 h by 51.23%. |
Cell Cycle Analysis[1] | Cell Line: | MCF-7 and Hela cells | | Concentration: | 10 mg/mL | | Incubation Time: | 24 hours | | Result: | Enhanced late apoptotic induction with 14.11% at Hela cells. |
|
| 分子量 | |
| Formula | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com